Post on 24-Apr-2023
This article was published in an Elsevier journal. The attached copyis furnished to the author for non-commercial research and
education use, including for instruction at the author’s institution,sharing with colleagues and providing to institution administration.
Other uses, including reproduction and distribution, or selling orlicensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of thearticle (e.g. in Word or Tex form) to their personal website orinstitutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies areencouraged to visit:
http://www.elsevier.com/copyright
Author's personal copy
Molecular determinants of Pb2+ interaction with NMDA
receptor channels
Paola Gavazzo, Ilaria Zanardi, Irena Baranowska-Bosiacka 1,Carla Marchetti *
Istituto di Biofisica, Consiglio Nazionale delle Ricerche, via De Marini 6, 16149 Genova, Italy
Received 23 January 2007; received in revised form 26 June 2007; accepted 3 July 2007
Available online 10 July 2007
Abstract
Lead (Pb2+) is a potent neurotoxin that acts as a non-competitive, voltage-independent antagonist of the NMDA receptor (NR) channel. Pb2+
action partially overlaps with that of zinc (Zn2+), but precise coincidence with Zn2+ binding site is debated. We investigated the site of Pb2+
interaction in NR channels expressed in Xenopus laevis oocytes from the clones z1, e1 or e2 and mutated e1 or e2 forms. For each e subunit we chose
two mutations that have been identified as ‘strong mutations’ for Zn2+ binding and examined the effect of Pb2+ on channels that contained those
mutations. In e1-containing channels, mutations D102A and H128A caused a decrease of Pb2+ inhibition with a 10-fold (D102A) and four-fold
(H128A) shift of IC50. In e2-containing channels, the most effective mutation in removing Pb2+ inhibition was H127A, with a five-fold increase of
IC50, while D101A was virtually ineffective. Other mutations, D104A, T103A, and T233A, were less effective. The double mutation
D101AH127A, while reducing Zn2+ inhibition by nearly nine-fold, caused a minor (less than two-fold) shift in Pb2+ IC50. Competition
experiments showed that increasing doses of Zn2+ reduced the apparent affinity for Pb2+ in e1-containing receptors, but not in e2-containing
receptors. In addition the effect of Pb2+ on e2-containing channels was additive with that of ifenprodil, with no competition for the site. Although
none of the mutations that we have tested abolished the block by Pb2+, our results indicate that the action of this toxic metal on NR channels is more
dependent on the receptor composition than previously thought, because Zn2+ is able to displace Pb2+ from its binding site in e1-containing
channels, but not in e2-containing channels.
# 2007 Elsevier Ltd. All rights reserved.
Keywords: Glutamate receptors; NMDA receptor subunits; Heavy metals; Zinc; Amino terminal domain; Neurotoxicity
Lead (Pb2+) has been known since a long time as a potent
central neurotoxin that interferes with neuronal functions and
causes a wide variety of long lasting adverse effects, especially
in developing brains (Toscano and Guilarte, 2005). Similar to
other heavy metals, Pb2+ may exert its action through
mimicking physiological metals, primarily calcium (Ca2+)
and zinc (Zn2+), possibly competing for their binding sites
(Marchetti, 2003).
One putative site of interaction of Pb2+ in the central nervous
system is the NMDA subtype of glutamate receptor (NR), a
receptor channel involved in many forms of synaptic plasticity
and in high brain functions, such as memory and spatial
learning, cognition and behavior. The NR channel carries the
‘‘slow’’ component of the glutamate-activated post synaptic
current and it is endowed with some unique properties, such as
the requirement for two agonists, glutamate and glycine, a
Mg2+-mediated voltage-dependence and significantly high
calcium permeability. All functional NRs are tetrameric
complexes, containing the essential subunit NR1 (rat) or z1
(mouse), which exists in eight splice variants, and one or more
of the four different NR2 types (NR2A, B, C and D, rat) or e1
through e4 (mouse). The NR2 pattern of expression is tissue-
dependent and differs remarkably during development (Aka-
zawa et al., 1994; Farrant et al., 1994).
Divalent cations deeply and specifically affect the function
of NR channels. Ault et al. (1980) first recognized two distinct
effects of divalent cations on the NR channel: the Mg-like effect
(voltage-dependent block), mimicked by Co, Ni and Mn, and
www.elsevier.com/locate/neuint
Neurochemistry International 52 (2008) 329–337
* Corresponding author. Tel.: +39 010 6475578; fax: +39 010 6475500.
E-mail address: marchett@ge.ibf.cnr.it (C. Marchetti).1 Present address: Department of Biochemistry and Medical Chemistry,
Pomeranian Medical University, Szczecin, Poland.
0197-0186/$ – see front matter # 2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2007.07.003
Author's personal copy
the Ca-like effect (permeation), which is mimicked by Sr, Ba
and Cd. Shortly after, Zn2+ was recognized to behave in a third
different way, with both voltage-dependent and voltage-
independent inhibitory effects (Westbrook and Mayer, 1987).
The voltage-independent Zn2+ inhibition is subunit-dependent
(Paoletti et al., 1997; Choi and Lipton, 1999) as the metal binds
with nanomolar affinity to a site in NR2A amino terminal
domain (ATD; Fayyazuddin et al., 2000; Low et al., 2000) and
with micromolar affinity to a site located in the same region of
NR2B (Rachline et al., 2005). Binding of Zn2+ restrains the
receptor activity and may regulate the amplitude of NMDA
synaptic currents (Erreger and Traynelis, 2005), so that free
Zn2+ has been suggested to act as an ‘‘atypical neurotransmit-
ter’’ (Baranano et al., 2001).
The inhibitory effect of Pb2+ on NR channels was early
described as a highly specific, voltage-independent, non-
competitive allosteric interaction (Alkondon et al., 1990;
Guilarte and Miceli, 1992; Busselberg et al., 1994), which
resembles the effect of Zn2+. However, Pb2+ has no Mg-like
voltage-dependent effect and does not discriminate signifi-
cantly between NR2A-, NR2B- and NR2C-containing
receptors (Yamada et al., 1995; Omelchenko et al., 1996,
1997). Evidence of competition of Pb2+ and Zn2+for the same
binding site was suggested in two studies (Guilarte et al., 1995;
Schulte et al., 1995) that reported an increase in the IC50 for
Pb2+ inhibition of MK-801 binding in the presence of Zn2+. In
these early works, Pb2+ potency was determined based on
nominal concentration. As Pb2+ forms complexes and
precipitates and is present as a contaminant in laboratory
reagents, further studies employed a divalent chelating agent
and measured the free metal concentration by a Pb2+-sensitive
electrode, establishing the IC50 for Pb2+-binding on the NR
channel in the low mM range (Lasley and Gilbert, 1999) and
confirming that, different from Zn2+, Pb2+ modulation of NR
channels is largely subunit-independent (Gavazzo et al., 2001;
Marchetti and Gavazzo, 2005). Moreover, Lasley and Gilbert
(1999), using a [3H]-MK801binding assay under equilibrium
conditions, showed that the interaction between of Zn2+ and
Pb2+ is non-competitive, questioning that they share the same
binding site.
Because of lack of both conclusive electrophysiological data
and structural evidences, competition between Zn2+ and Pb2+,
as well as the location of the Pb2+ binding site, are still
undefined. Thus we decided to investigate directly the structural
determinants of Pb2+ interaction with NR and started this study
by examining the effect of point mutations at the Zn2+ binding
site in e1 and e2, the mouse forms of NR2A and NR2B subunits.
Our first aim was to determine whether Pb2+ and Zn2+ compete
for the same binding site and we show here that competition is
dependent on the subunit present.
1. Experimental procedure
1.1. In vitro transcription and functional expression in Xenopus
oocytes
NMDA receptor subunit mouse clones z1 (GenBank number D10028), e1
(GenBank number D10217) and e2 (GenBank number D10651) were gener-
ously provided by M. Mishina (University of Tokio, Japan). Mutant clones were
obtained by using the QuikChange Site-Directed Mutagenesis kit (Stratagene,
La Jolla, CA, USA). All mutants were verified by dideoxy sequencing across the
mutated region (Sanger et al., 1977). cRNAs were synthesized in vitro from
linearized templates of cDNA using SP6 RNA polymerase from Ambion
(Austin, TX, USA; Yamakura et al., 1993). cRNA was quantified by optical
density at 260 nm and visualized on an agarose gel by ethidium bromide in
order to verify the integrity of the synthesized molecules. Oocytes were
obtained from large females of Xenopus laevis (CNRS, Montpellier, France).
The ovarian lobes were surgically removed and the oocytes separated and
treated for 2 h with collagenase type IA (1 mg/ml), in a Ca-free solution. A
volume of 10–30 nl containing an equal amount of z1 and either e1 or e2 (wild
type or mutated form) cRNA (0.1–0.5 mg/ml) was injected in each oocyte by
means of a Nanoliter 2000 automatic injector (WPI, Sarasota, FL, USA). Cells
were incubated at 19 8C in Barth’s solution, containing (in mM) 88 NaCl, 1 KCl,
0.82 MgSO4, 0.33 Ca(NO3)2, 0.41 CaCl2, 2.4 NaHCO3, 5 Tris–HCl, 5 HEPES
(pH 7.4) and supplemented with 50 mg/ml gentamycin and 100 mM � 2-amino-
5-phosphopentanoic acid (D-AP5). Channel expression was obtained 24–48 h
after injection.
1.2. Electrophysiology
Oocytes were voltage-clamped by two electrodes, which were filled with
3 M KCl solution and had a resistance of 0.1–1 MV. The bath solution
contained (in mM): NaCl 100, KCl 2.8, Hepes 5, glycine 0.03 and 1.8 mM
CaCl2 and 3 mM Na-citrate, when the effect of Pb2+ alone was tested, or 2 mM
CaCl2 and 5 mM Na-citrate, when testing the effect of Zn2+ or of both Pb2+ and
Table 1
Measured free concentrations of Pb2+ in the different experimental conditions
Pb added
(mM)
Pb free (mM) in 3 mM
Na-citrate + 1.8 mM
CaCl2 (no Zn added)
Pb free (mM) in 5 mM
Na-citrate + 2 mM
CaCl2 + 0.2 mM Zn
Pb free (mM) in 5 mM
Na-citrate + 2 mM
CaCl2 + 0.5 mM Zn
Pb free (mM) in 5 mM
Na-citrate + 2 mM
CaCl2 + 1 mM Zn
1 0.07 � 0.01 – 0.04 � 0.02 –
5 0.21 � 0.06 – 0.08 � 0.02 –
10 0.30 � 0.03 0.09 � 0.04 0.12 � 0.03 0.21 � 0.11
30 0.50 � 0.01 0.25 � 0.03 0.27 � 0.09 0.29 � 0.04
50 0.69 � 0.05 – 0.38 � 0.08 –
100 1.39 � 0.13 0.56 � 0.08 0.62 � 0.08 0.88 � 0.02
150 1.86 � 0.27 – 0.90 � 0.08 –
200 2.52 � 0.37 1.21 � 0.10 1.23 � 0.26 –
300 3.40 � 0.48 1.31 � 0.37 1.69 � 0.18 2.17 � 0.06
500 5.41 � 0.60 2.35 � 0.48 2.89 � 0.23 3.44 � 0.4
Values are mean � S.E.M. in at least five measurements in control or in the presence of agonists glycine (30 mM) and glutamate (50 mM). Details are described in
Section 1.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337330
Author's personal copy
Zn2+ (see below). The pH was 7.4. Recordings were performed with a Turbo
TEC-03X amplifier (Npi Electronic, Tamm, Germany) and digitized by a
National Instrument BNC-2090 AD/DA converter at 1 kHz. Glutamate
(50 mM), as well as different concentration of Pb2+ and Zn2+, were applied
by gravity flow. The inhibitory effect of the metals was measured on the steady-
state current at �60 mV.
1.3. Lead and zinc solutions
Lead solutions were prepared daily from a stock solution of lead perchlorate
standard (0.1 M, Orion Research, Beverly, MA) and handled in plasticware.
Zinc was prepared as a stock solution of 100 mM ZnCl2 and diluted daily. The
chelating agent sodium citrate (3 mM) was used to set the free Pb2+ concentra-
tion in the bath, as in our previous work (Gavazzo et al., 2001). This chelator
appeared the more suitable to set Pb2+ concentration in an appropriate range at
pH 7.4. When both Pb2+ and Zn2+ were present, the concentration of the
chelating agent was elevated to 5 mM to increase the buffer potency, as in
Lasley and Gilbert (1999). Free ionic Pb2+ concentration in the solutions was
measured by a Pb-sensitive electrode (Orion 96-82), calibrated by the method of
Kivalo et al. (1976) against nitrilotriacetate (NTA)-buffered solutions at dif-
ferent pH, as described in Simons (1985) and in our previous work (Gavazzo
et al., 2001). The concentration of free Pb2+ in the calibrating buffers, as well as
concentrations of free Zn2+ and Ca2+ in the different solutions (see below), were
calculated by Maxchelator 2.5 software (www.stanford.edu/�cpatton/
maxc.html), assuming a temperature of 20 8C, and an ionic strenght
120 mM. The metal-ligand stability constants for citrate and NTAwith different
metals are those provided with the above quoted freeware software and are
listed at http://www.stanford.edu/�cpatton/xlsconstants.htm. The concentra-
tions of free Pb2+ measured by the Pb-sensitive electrode in the different
conditions are showed in Table 1. The values represent the mean � S.E.M.
of 5–12 measurements for each dose and were independent of the presence of
the agonists in the solution. The measured values were considered more reliable
than those obtained by software calculation. Free Zn2+ and Ca2+ were calculated
by the above software at pH 7.4. In the solution containing 3 mM citrate and
1.8 mM CaCl2, free Ca2+ ranged from 0.34 to 0.43 mM depending on the
concentration of Pb2+ added (0–500 mM). This value of free Ca2+ was in
agreement with that we measured by Fura-2 fluorescence in a previous study
(Mazzolini et al., 2001). In 5 mM citrate and 2 mM CaCl2, free Ca2+ ranged
from 0.20 to 0.23 mM with 0–500 mM Pb2+ added, and from 0.2 to 0.27 mM in
0 Pb2+ and 0–1 mM Zn2+ added. The calculated concentrations of free Zn2+ in
the different conditions are listed in Table 2. Note that free Zn2+ is dependent on
added Pb2+; however, we verified that these variations do not alter significantly
the results described in Figs. 4 and 5, where approximated values of free Zn2+
are indicated for simplicity.
1.4. Data analysis
The software for the acquisition and analysis of data was developed by
Michael Pusch and it is freely available at http://www.ge.cnr.it/ICB/conti_mor-
an_pusch/programs-pusch/programs-mik.htm. Curve fitting was performed by
Sigma Plot (SPSS Science, Chicago, IL, USA) software. Data are shown as
mean � S.E.M.
Inhibition curves were generated by fitting experimental points to a single
binding site isotherm with equation:
I
Icontrol
¼ 1
½1þ ðPb2þ=IC50ÞnH �
(1)
where I/Icontrol is the average value of the fraction of current resistant to Pb2+
inhibition, [Pb2+] the free Pb2+ concentration, IC50 the free Pb2+ dose which
provokes a 50% block of the NR current and nH is the Hill coefficient.
Competition of Zn2+ and Pb2+ for the same binding site was evaluated by the
equation
KðPbÞ�d ¼ K
ðPbÞd
�1þ ½Zn2þ�
KdðZnÞ
�(2)
where KðPbÞ�d is the apparent dissociation constant, K
ðPbÞd the dissociation
constant in the absence of Zn2+, KðZnÞd the Zn2+ dissociation constant in the
absence of Pb2+ and [Zn2+] is the free Zn2+ concentration.
2. Results
The residues important for the voltage-independent Zn2+
interaction have been previously identified in the amino
terminal domain (ATD) region of both e1 (NR2A) and e2
(NR2B) subunit. We chose two mutations for each subunit that
have been identified as ‘strong mutations’ for Zn2+ binding and
examined the effect of Pb2+ on channels that contained those
mutations. In e1 subunit, we investigated the mutants D102A
and H128A, which have been reported to exhibit a strongly
reduced zinc sensitivity (Fayyazuddin et al., 2000; Low et al.,
2000; Paoletti et al., 2000). Both these mutations partially
reduced the block exerted by Pb2+, as shown in Fig. 1. Currents
were normalized to the plateau value of the current before
(control) or after (wash) the treatment with Pb2+. The effect of
the metal was always entirely reversible. In channels containing
the wild type form of e1 subunit, the largest dose of Pb2+ (7 mM)
blocked the NR current by 85 � 2% (n = 22). Higher doses of
Pb2+ were not tested because of the limited solubility of the
metal at physiological pH (Simons, 1985; Lasley and Gilbert,
1999). Experimental points were well fitted by Eq. (1) and the
best fit gave IC50 = 1.3 mM (nH = 1.0) for channels containing
the wild type form of e1. Mutation D102A reduced the block
caused by 7 mM Pb2+ to 40 � 5% (n = 6) and caused also a 10-
fold shift of IC50 (to 11.3 mM, nH = 1.0). Mutation H128A
caused a less prominent reduction of the block and a three-fold
shift of IC50 (to 3.3 mM, nH = 0.85). Fig. 1(C) represents the
Table 2
Calculated free concentrations of Zn2+ in the different experimental conditions,
as a function of added Zn2+ in the absence of Pb2+ (top) and of added Pb2+ at
three different concentrations of added Zn2+ (bottom)
Zn added (mM) (0 Pb added) Zn free (mM)
1 0.004
10 0.043
100 0.43
150 0.67
200 0.80
300 1.38
500 2.50
1000 6.03
Pb added (mM) Zn free (mM)
+200 mM Zn +500 mM Zn +1 mM Zn
0 0.80 2.50 6.03
5 0.91 2.50 6.05
10 0.91 2.50 6.06
30 0.92 2.54 6.11
50 0.93 2.56 6.15
100 0.94 2.60 6.28
150 0.96 2.65 6.41
200 0.97 2.69 6.54
300 1.01 2.79 6.82
500 1.08 3.01 7.45
The solution contained 5 mM Na-citrate and 2 mM CaCl2. Details of the
calculation are described in Section 1.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337 331
Author's personal copy
ratio of the Pb2+ IC50 for mutant receptors over that of e1 wild
type receptors.
In wild type e2-containing channels, the current was blocked
by 91 � 2% (n = 17) in the presence of the largest concentra-
tion of Pb2+, and the best fit of the inhibition curve yielded a
value of IC50 = 1.2 mM (nH = 1.0). For this channel, we tested
the corresponding mutations H127A and D101A, which have
been recognized among those capable to shift the Zn2+
inhibition dose-dependence significantly (Rachline et al.,
2005). Mutation D101A did not change Pb2+ sensitivity,
whereas mutation H127A reduced the maximum current block
to one half with respect to the wild type current and shifted the
IC50 to 6.9 mM (Fig. 2).
We tried to find other mutations that affected Pb2+ block in
e2-containing channel more efficiently and tested T103A and
T233A, which shift up to five-fold the IC50 for Zn2+ (Rachline
et al., 2005) and mutation D104A, which does not alter Zn2+
interaction, but profoundly modifies the inhibition by the
phenolethanolamine ifenprodil or its analog RO 25-6981
(Perin-Dureau et al., 2002; Malherbe et al., 2003). All these
mutations modified the dose-dependence of Pb2+ inhibition
slightly, but less effectively than H127A (Fig. 2(B and C)).
Then we tested the effect of Pb2+ on the NR current with e2-
containing the double mutation D101AH127A. The maximum
dose of Zn2+ (6.5 mM) blocked the current of the wild type
channel by 89 � 3% (n = 8) and the current of the double
mutated channel by 54 � 3% (n = 12), with a shift of the IC50
for Zn2+ from 0.6 to 5.2 mM (Fig. 3(A)). The double mutation
was less effective on Pb2+ block, with a reduction of the block
caused by 3.4 mM free Pb2+ from 78 � 3% (n = 12) to 62 � 2%
Fig. 1. Effect of Pb2+ on NR containing z1 and wild type (wt) or D102A and H128A mutated forms of e1. Currents were elicited by 50 mM glutamate in the presence
of 30 mM glycine at a membrane potential of �60 mV. The bath solution contained 3 mM Na-citrate. Free Pb2+ concentrations were measured by a Pb-sensitive
electrode as described in the text. (A) Traces show the current block caused by increasing concentrations of Pb2+ in e1-containing channels. Vertical arrows indicate
application of 0.3, 1.4, 3.4, 5.4 and 7 mM free Pb2+, respectively. The control steady state currents were 22 and 18 mA for wild type and D102A mutation, respectively.
(B) Dose-dependence curve of the effect of Pb2+ for channels containing wild type (wt) or mutated e1. Current values were normalized to Icontrol, the value of the
current in the absence of Pb2+. Points represent averages of at least six measurements and are fitted to Eq. (1). In the wt channel, IC50 was of 1.3 mM, nH = 1.0; in the
H128A mutant, IC50 was 3.3 mM, nH = 0.85 and in D102A mutant, 11.3 mM, nH = 1.0. (C) Ratio of the Pb2+ IC50 for mutant receptors over that of e1 wild type (wt)
receptors.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337332
Author's personal copy
(n = 4) and a shift of IC50 for Pb2+ from 1.2 to 1.9 mM
(Fig. 3(B)).
In order to elucidate a possible competition between Zn2+
and Pb2+ directly, we measured the effect of Pb2+ in wild type
channels in the presence of fixed concentrations of Zn2+ (1, 2.6
or 6.5 mM). Results are showed in Fig. 4, for e1-containing
receptors and in Fig. 5 for e2-containing receptors. In the
presence of 3 mM Na-citrate solution, the basal Zn2+ present in
the solution is sequestered by the chelator and therefore the free
Zn2+ is negligible. This is shown in Fig. 4(A) where the current
through e1-containing channels is significantly bigger in 3 mM
Na-citrate than in a basal solution, containing no chelators, in
agreement with previous observations (Paoletti et al., 1997). A
further increase in the citrate concentration (up to 5 mM) did
not determine any further increase in the current amplitude.
Therefore the KðPbÞd equal to 1.3 mM in e1-containing receptors
and 1.2 mM in e2-containing receptors reflect the interaction of
Pb2+ with the channel in the absence of Zn2+. In e1-containing
receptors, the presence of Zn2+ modifies the block by Pb2+. In
the presence of Zn2+ and 5 mM citrate, the maximum amount of
Pb2+ added was 500 mM in all solutions. The concentration of
free Pb2+ was measured and found equal to 2.4 � 0.5 mM in
1 mM Zn2+, 2.9 � 0.2 mM in 2.6 mM Zn2+ and 3.4 � 0.4 mM in
6.5 mM Zn2+ (see Table 1). Those doses of Pb2+ determined a
block of less than 50% in each case (38 � 3%, 31 � 1%, and
20 � 3%, respectively; Fig. 4(B)). Best fit with Eq. (1) yielded
an estimate for the IC50, which was shifted from 1.3 mM (in
control conditions, 3 mM citrate and 0 Zn2+ added) to 3.8 in
1 mM free Zn2+, 7.1 mM in 2.6 mM free Zn2+ and to 19.4 mM in
6.5 mM free Zn2+. Under the assumption that Zn2+ and Pb2+
compete for the same binding site, we best fitted these values to
Eq. (2) and obtained a value of 0.48 mM for KðZnÞd (Fig. 4(B),
inset).
In contrast, in e2-containing receptors, the dose-dependence
of Pb2+ inhibition was not significantly modified in the presence
of increasing doses of Zn2+. The largest dose of Pb2+ added
caused a > 80% block, with IC50 close to 1.2 mM, in all cases
(Fig. 5).
Fig. 2. Effect of Pb2+ on NMDA receptors containing z1 and wild type (wt) or mutated forms of e2. Currents were elicited by 50 mM glutamate in the presence of
30 mM glycine at a membrane potential of �60 mV. The bath solution contained 3 mM Na-citrate. Free Pb2+ concentrations were measured by a Pb-sensitive
electrode as described in the text. (A) Traces show the current block caused by increasing concentrations of Pb2+ in e2-containing channels. Vertical arrows indicate
application of 0.3, 1.4, 3.4, 5.4 and 7 mM free Pb2+, respectively. The control steady state currents were 2.5, 2.2 and 2.8 mA for wild type, D101A and H127A
mutation, respectively. (B) Dose-dependence curve of the effect of Pb2+ for channels containing wild type (wt) or mutated e2. Current values were normalized to
Icontrol, the value of the current in the absence of Pb2+. Points are averages of at least six measurements and are fitted to Eq. (1). In the wild type channel, IC50 had a
value of 1.2 mM, nH = 1.1; in D101A mutant the same parameters had values 1.0 mM and 1.0; in T233A, 1.7 mM and 1.2; in T103A, 2.7 mM and 1.3; in D104A,
3.2 mM and 1.3, and finally in H127A, 6.9 mM and 0.8. (C) Ratio of the Pb2+ IC50 for mutant receptors over that of e2 wild type (wt) receptors.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337 333
Author's personal copy
Finally, and because the D104A mutation caused a shift of
IC50 for Pb2+, we tested if Pb2+ competes for the same site as
ifenprodil, as it has been shown for Zn2+. These experiments
were designed as in Rachline et al. (2005). Binding and
unbinding of ifenprodil to its site is significantly slower than
that of divalent cations. Similar to Zn2+, unbinding of Pb2+
developed with a time constant of 2 s (Fig. 6(A)), while
ifenprodil unbound from its site with a time constant of
approximately 100 s (Fig. 6(B)). Then the two blockers were
applied together in sequence. First, ifenprodil was applied at a
concentration (200 nM) to occupy half of its binding sites and
subsequently a high (7 mM) concentration of Pb2+ was applied
for several minutes. This dose of Pb2+ should be able to displace
ifenprodil in the case the two binding sites are coincident and, if
this is the case, a single, fast off-relaxation time-course should
result in wash. However, the off-relaxation curve showed a
double exponential time-course, with a fast (2 s time constant)
and a slow (100 s time constant) component of equal weight
(Fig. 6(C and D)), suggesting that the effect of Pb2+ on e2-
containing channels is additive with that of ifenprodil, with no
competition for the binding site.
3. Discussion
In this work, we have presented new data on the putative
Pb2+ binding site on the NR channel. Because of previous
(Guilarte et al., 1995; Schulte et al., 1995), although
controversial (Lasley and Gilbert, 1999), evidences, we started
our investigation from the assumption that Pb2+ binds to or
close to the Zn2+ binding site. We took advantage of the most
Fig. 3. Dose-dependence of the inhibitory effects of Zn2+ and Pb2+ on NMDA
receptors containing z1 and wild type (circles) or double-mutated
D101AH127A (triangles) e2. Currents were elicited by 50 mM glutamate in
the presence of 30 mM glycine at a membrane potential of �60 mV. Current
values were normalized to Icontrol, the value of the current in the absence of Zn2+
or Pb2+. Points represent averages of at least six measurements and were fitted to
Eq. (1). (A) Dose-dependence curve of Zn2+ inhibition. The bath solution
contained 5 mM Na-citrate and free Zn2+ concentrations were calculated as
described in the text. The IC50 was 0.6 mM (nH = 0.95) in the wild type (circles)
and 5.2 mM (nH = 0.73) in the double mutant (triangles). (B) Dose-dependence
curve of Pb2+ inhibition. The bath solution contained 3 mM Na-citrate. The
double mutation shifted the IC50 from 1.2 mM in control (nH = 1.1, circles) to
1.95 mM (nH = 0.9, triangles).
Fig. 4. Effect of citrate and of Pb2+ in the presence of Zn2+ in NR channels
containing z1 and wild type e1. Currents were elicited by 50 mM glutamate in
the presence of 30 mM glycine at a membrane potential of�60 mV. (A) Current
traces showing the response to 50 mM glutamate in the presence of 30 mM
glycine at a membrane potential of �60 mV in a solution without divalent
chelators (left) and in 3 mM Na-citrate (right). Further elevation of citrate
concentration to 5 mM did not produce any further change in the current. (B)
Dose-dependence curve of Pb2+ inhibition in the presence of the indicated
concentration of Zn2+ for channels containing wild type e1. The bath solution
contained 5 mM Na-citrate. Current values were normalized to Icontrol, the value
of the current in the absence of Pb2+. Points represent averages of at least four
measurements and were fitted to Eq. (1). The IC50 was shifted from 1.3 mM
(nH = 1.0) in Pb2+ alone, to 3.8 mM (nH = 0.9) in 1 mM, to 7.1 mM (nH = 0.8) in
2.6 mM and to 19.4 mM (nH = 0.8) in 6.5 mM free Zn2+. The inset shows the
dependence of the apparent dissociation constant KðPbÞ�d on the free Zn2+
concentration and the straight line is the best fit with Eq. (2). See text for
explanation.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337334
Author's personal copy
recent findings concerning the location of the Zn2+ binding
domain on e (NR2) subunits, selected some residues that have
been shown to be involved in Zn2+ interaction and investigated
how the same residues may influence Pb2+ interaction.
In NR2A, or e1, subunit, residues D102 and H128 are both
located in a region lining the putative Zn2+ binding cleft and it
has been shown that a substitution by either A or S strongly
reduces the Zn2+ binding affinity (Fayyazuddin et al., 2000;
Paoletti et al., 2000; Low et al., 2000). The two point mutations
D102A and H128A affected Pb2+ inhibition, with D102A being
more effective. In NR2B, or e2 subunit, the corresponding D101
and H127 residues have been shown to control intermediate
affinity Zn2+ inhibition (Rachline et al., 2005), as well as
inhibition by the NR2B-selective antagonist ifenprodil (Perin-
Dureau et al., 2002; Rachline et al., 2005) and its analog RO 25-
6981 (Malherbe et al., 2003). Only mutation H127A modified
the blocking properties of Pb2+. The point mutation D101A,
which was shown to affect profoundly not only Zn2+, but also
ifenprodil inhibition (Malherbe et al., 2003; Rachline et al.,
2005), had no effect on Pb2+ action (Fig. 2). We also tested other
three point mutations in the ATD of e2 subunit: T103A and
T233, mutations that affect both ifenprodil and Zn2+ inhibition,
and D104A, a mutation that decreases only ifenprodil
sensitivity (Rachline et al., 2005), but none of these mutations
was more effective than H127A on Pb2+ inhibition. Finally, the
double mutant D101AH127A caused a larger shift in Zn2+
inhibition than in Pb2+ inhibition. However both shifts were of a
lesser extent than that caused by H127A mutation alone. This
can be explained by the proximity and close interaction of the
two residues. When substituted amino acids are near to or in
direct contact with each other, the effects are often highly non-
additive, because each mutation affects the environment of the
Fig. 5. Dose-dependence curve of Pb2+ inhibition in the presence of the
indicated concentration of Zn2+ for channels containing wild type e2. Currents
were elicited by 50 mM glutamate in the presence of 30 mM glycine and 5 mM
Na-citrate at a membrane potential of�60 mV. Current values were normalized
to Icontrol, the value of the current in the absence of Pb2+. Points represent
averages of at least five measurements. The solid line shows the best fit with
Eq. (1) in the absence of Zn2+ (same as in Fig. 2). The IC50 was close to 1.2 mM
in all cases.
Fig. 6. Evidence for lack of competition for the same binding site between Pb2+ and ifenprodil in channels containing wild type e2. Currents were elicited by 50 mM
glutamate in the presence of 30 mM glycine at a membrane potential of�60 mV. (A–C) Current traces illustrating the effect on the steady-state current of 7 mM Pb2+
alone (A), 200 nM ifenprodil alone (B) and application in sequence of the two blockers, with simultaneous removal (C). The high dose of Pb2+ (7 mM) blocked the
current almost completely, while 200 nm ifenprodil caused a 50% inhibition with slower on and off rates. The time course of current recovery after the combined
application displays two components, corresponding to the sum of the two individual off-relaxation curves. (D) Off-relaxation time courses shown on an expanded
scale. Circles: 7 mM Pb2+; the best fit with a single exponential decaying function gave a time constant of 2 s. Squares: 200 nM ifenprodil only, the best fit gave a time
constant of 100 s. Triangles: time course of simultaneous removal of the two agonists, the best fit with the sum of two exponential decaying functions yielded 2 and
100 s time constants, with equal weight.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337 335
Author's personal copy
other (Wells, 1990; Skinner and Terwilliger, 1996). The effects
of such two mutations can be antagonistic or synergistic, with
respect to a particular function, and in this case the double
mutant pertubs the system less than the two individual mutants.
Although these data confirmed an interaction of Pb2+ in the
ATD of e1 and e2 subunit, they also suggested a difference
between the two channel types, because a residue of the e1 high-
affinity binding site for Zn2+ (D102) is important for Pb2+
inhibition, while a residue controlling the e2 intermediate-
affinity site for Zn2+ (D101) is not. This difference was
confirmed by direct competition experiments. In e1-containing
channels, Pb2+ inhibition curve was shifted in the presence of
increasing doses of Zn2+, suggesting a partial overlap or close
interaction of the two binding sites (see later). In contrast, in e2-
containing channels, we did not observe any shift in the Pb2+
dose-dependence curve in the presence of Zn2+, suggesting that
despite some involvement of the same residue (H127) in both
Pb2+ and Zn2+ interaction, the two binding sites are distinct.
This latter conclusion finds an indirect confirmation in the
observation that Pb2+ binds to a site that is distinct from that of
ifenprodil (Fig. 6). In contrast, it has been shown that this
specific NR2B antagonists binds in the ATD (Perin-Dureau
et al., 2002) to a site overlapping with that for Zn2+ (Rachline
et al., 2005).
While the absence of an apparent competition indicates that
in e2-containing channels Pb2+ binds to a site distinct from that
for Zn2+ and ifenprodil, in e1-containing channels, the
competition observed between Pb2+ and Zn2+ does not imply
necessarily that the two metal bind to the same site, but possibly
that when Pb2+ occupies its site, it modifies Zn2+ binding. From
the data shown in Fig. 4, Pb2+ appears to compete for a Zn2+
binding site whose affinity can be estimated of 0.48 mM, a value
20–30-fold larger than that reported for the high affinity Zn2+
binding measured with tricine as chelator (Paoletti et al., 1997).
This discrepancy can be due to several factors. First, the
inhibition curves (Fig. 4(B)) do not reach 50% block, so that
IC50 values are undefined and the extent of the shift most likely
underestimated. Then, and more significantly, it is entirely
possible that Pb2+ is not capable to fully displace Zn2+ from its
site or that the two binding sites are not exactly overlapping. It
has been recently proposed that allosteric modulators, Zn2+ and
phenolethanolamines (such as ifenprodil), as well as Pb2+, act
through regulatory sites that are located in the ATD, but are
coupled to the agonist binding site and stabilize the non-
conducting desensitized configuration (Erreger and Traynelis,
2005; Huggins and Grant, 2005). Therefore, it is possible that
when Zn2+ occupies its site, it decouples Pb2+ binding and
channel closure, even if the two binding sites are not coincident.
The difference between e1-containing and e2-containing
channels may have some interesting outcome, because Zn2+ is
able to displace Pb2+ from it binding site in e1-containing
channels, but not in e2-containing channels. In basal
physiological conditions, when Zn2+ occupies the e1 high
affinity site, the IC50 for Pb2+ would be different from the value
we have measured in 0 free Zn2+ (1.3 mM), with IC50 increasing
by a factor of 3 in 1 mM free Zn2+; on the contrary the IC50 in
e2-containing channels is close to 1 mM irrespective of free
Zn2+ concentration, resulting in a different sensitivity to Pb2+ in
the two receptor types when free Zn2+ is not negligible.
It should be noted that, with either subunit, the shifts we
observed in the dose-dependent curve are always not very
prominent, so that additional structural elements beside the
residues we have mutated must contribute to Pb2+ binding. In
the case of Zn2+ binding to NR2B-containing receptors, the
existence of an additional low-affinity site located in a region
different from ATD, was also suggested (Rachline et al., 2005).
As for Pb2+, earlier studies provided biochemical evidence for
two sites of interaction on the NR channel (Guilarte, 1997), one
of higher affinity, with IC50 ranging from 0.3 to 4.7 mM and a
second of lower affinity (IC50 � 70 mM), and whose relative
abundance was related to development and to different
populations of NRs. However, those values were based on
nominal metal concentrations and cannot be directly compared
to the values observed in the current study. In another study,
using free metal ion concentrations, Lasley and Gilbert (1999)
observed only one allosteric binding site, with IC50 close to
0.6 mM. All these authors worked with native channels, whose
composition in subunits is not known and frequently
heterotrimeric, that is they contain two different types of e(NR2) subunit; so their results cannot be directly related to our
data, which were obtained in oocytes injected with only one
type of e subunit and expressing a channel protein of defined
composition. In addition, a role of the z1 subunit, which was
never mutated in this study, and of its different splice variants,
would also require attention, because it is likely it partecipates
to Pb2+ binding site, as it does to the Zn2+ binding site
(Traynelis et al., 1998).
In conclusion, all the mutations tested, in either subunit, fell
short of abolishing Pb2+ block, suggesting the involvement of
additional structural elements, different from those important
for Zn2+ binding. This work is the first to address the problem of
the location of Pb2+ interaction site on NR channels from the
structural point of view and many possibilities are still open and
deserve further investigation. Our study indicates that the effect
of Pb2+ on NR channels is more dependent on the receptor
composition than previously thought. In e1-containing chan-
nels, some residues that are important for high affinity binding
of Zn2+ participate in Pb2+ interaction and Zn2+ is able to
displace Pb2+ from its binding site, while this is not observed in
e2-containing channels.
References
Akazawa, C., Shigemoto, R., Bessho, Y., Nakanishi, S., Mizuno, N., 1994.
Differential expression of five N-methyl-D-aspartate receptor subunit
mRNAs in the cerebellum of developing and adult rats. J. Comp. Neurol.
347, 150–160.
Alkondon, M., Costa, A.C., Radhakrishnan, V., Aronstam, R.S., Albuquerque,
E.X., 1990. Selective blockade of NMDA-activated channel currents may be
implicated in learning deficits caused by lead. FEBS Lett. 261, 124–130.
Ault, B., Evans, R.H., Francis, A.A., Oakes, D.J., Watkins, J.C., 1980. Selective
depression of excitatory amino acid induced depolarizations by magnesium
ions in isolated spinal cord preparations. J. Physiol. 307, 413–428.
Baranano, D.E., Ferris, C.D., Snyder, S.H., 2001. Atypical neural messengers.
Trends Neurosci. 24, 99–106.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337336
Author's personal copy
Busselberg, D., Michael, D., Platt, B., 1994. Pb2+ reduces voltage- and N-
methyl-D-aspartate (NMDA)-activated calcium channel currents. Cell. Mol.
Neurobiol. 14, 711–722.
Choi, Y.B., Lipton, S.A., 1999. Identification and mechanism of action of two
histidine residues underlying high-affinity Zn2+ inhibition of the NMDA
receptor. Neuron 23, 171–180.
Erreger, K., Traynelis, S.F., 2005. Allosteric interaction between zinc and
glutamate binding domains on NR2A causes desensitization of NMDA
receptors. J. Physiol. 569, 381–393.
Farrant, M., Feldmeyer, D., Takahashi, T., Cull-Candy, S.G., 1994. NMDA-
receptor channel diversity in the developing cerebellum. Nature 368, 335–
339.
Fayyazuddin, A., Villarroel, A., Le Goff, A., Lerma, J., Neyton, J., 2000. Four
residues of the extracellular N-terminal domain of the NR2A subunit control
high-affinity Zn2+ binding to NMDA receptors. Neuron 25, 683–694.
Gavazzo, P., Gazzoli, A., Mazzolini, M., Marchetti, C., 2001. Lead inhibition of
NMDA channels in native and recombinant receptors. Neuroreport 12,
3121–3125.
Guilarte, T.R., 1997. Pb2+ inhibits NMDA receptor function at high and low
affinity sites: developmental and regional brain expression. Neurotoxicol-
ogy 18, 43–51.
Guilarte, T.R., Miceli, R.C., 1992. Age-dependent effects of lead on [3H]MK-
801 binding to the NMDA receptor-gated ionophore: in vitro and in vivo
studies. Neurosci. Lett. 148, 27–30.
Guilarte, T.R., Miceli, R.C., Jett, D.A., 1995. Biochemical evidence of an
interaction of lead at the zinc allosteric sites of the NMDA receptor
complex: effects of neuronal development. Neurotoxicology 16, 63–
71.
Huggins, D.J., Grant, G.H., 2005. The function of the amino terminal domain in
NMDA receptor modulation. J. Mol. Graph. Model. 23, 381–388.
Kivalo, P., Virtanen, R., Wickstrom, K., Wilson, M., 1976. An evaluation of
some commercial lead(II)-selective electrodes. Anal. Chim. Acta 87, 401–
409.
Lasley, S.M., Gilbert, M.E., 1999. Lead inhibits the rat N-methyl-D-aspartate
receptor channel by binding to a site distinct from the zinc allosteric site.
Toxicol. Appl. Pharmacol. 159, 224–233.
Low, C.M., Zheng, F., Lyuboslavsky, P., Traynelis, S.F., 2000. Molecular
determinants of coordinated proton and zinc inhibition of N-methyl-D-
aspartate NR1/NR2A receptors. Proc. Natl. Acad. Sci. U.S.A. 97,
11062–11067.
Malherbe, P., Mutel, V., Broger, C., Perin-Dureau, F., Kemp, J.A., Neyton, J.,
Paoletti, P., Kew, J.N., 2003. Identification of critical residues in the amino
terminal domain of the human NR2B subunit involved in the RO 25-6981
binding pocket. J. Pharmacol. Exp. Ther. 307, 897–905.
Marchetti, C., 2003. Molecular targets of lead in brain neurotoxicity. Neuro-
toxicity Res. 5, 221–236.
Marchetti, C., Gavazzo, P., 2005. NMDA receptors as targets of heavy metal
interaction and toxicity. Neurotoxicity Res. 8, 245–258.
Mazzolini, M., Traverso, S., Marchetti, C., 2001. Multiple pathways of Pb2+
permeation in rat cerebellar granule neurones. J. Neurochem. 79, 407–416.
Omelchenko, I.A., Nelson, C.S., Marino, J.L., Allen, C.N., 1996. The sensitivity
of N-methyl-D-aspartate receptors to lead inhibition is dependent on the
receptor subunit composition. J. Pharmacol. Exp. Ther. 278, 15–20.
Omelchenko, I.A., Nelson, C.S., Allen, C.N., 1997. Lead inhibition of N-
methyl-D-aspartate receptors containing NR2A, NR2C and NR2D subunits.
J. Pharmacol. Exp. Ther. 282, 1458–1464.
Paoletti, P., Ascher, P., Neyton, J., 1997. High-affinity zinc inhibition of NMDA
NR1-NR2A receptors. J. Neurosci. 17, 5711–5725.
Paoletti, P., Perin-Dureau, F., Fayyazuddin, A., Le Goff, A., Callebaut, I.,
Neyton, J., 2000. Molecular organization of a zinc binding N-terminal
modulatory domain in a NMDA receptor subunit. Neuron 28, 911–925.
Perin-Dureau, F., Rachline, J., Neyton, J., Paoletti, P., 2002. Mapping the
binding site of the neuroprotectant ifenprodil on NMDA receptors. J.
Neurosci. 22, 5955–5965.
Rachline, J., Perin-Dureau, F., Le Goff, A., Neyton, J., Paoletti, P., 2005. The
micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J.
Neurosci. 25, 308–317.
Sanger, F., Nicklens, S., Coulson, A.R., 1977. DNA sequencing with chain-
terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74, 5463–5467.
Schulte, S., Muller, W.E., Friedberg, K.D., 1995. In vitro and in vivo effects of
lead on specific 3H-MK-801 binding to NMDA-receptors in the brain of
mice. Neurotoxicology 16, 309–317.
Simons, T.J., 1985. Influence of lead ions on cation permeability in human red
cell ghosts. J. Membr. Biol. 84, 61–71.
Skinner, M.M., Terwilliger, T.C., 1996. Potential use of additivity of mutational
effects in simplifying protein engineering. Proc. Natl. Acad. Sci. U.S.A. 93,
10753–10757.
Toscano, C.D., Guilarte, T.R., 2005. Lead neurotoxicity: from exposure to
molecular effects. Brain Res. Brain Res. Rev. 49, 529–554.
Traynelis, S.F., Burgess, M.F., Zheng, F., Lyuboslavsky, P., Powers, J.L., 1998.
Control of voltage-independent zinc inhibition of NMDA receptors by the
NR1 subunit. J. Neurosci. 18, 6163–6175.
Wells, J.A., 1990. Additivity of mutational effects in proteins. Biochemistry 29,
8509–8517.
Westbrook, G.L., Mayer, M.L., 1987. Micromolar concentrations of Zn2+
antagonize NMDA and GABA responses of hippocampal neurons. Nature
328, 640–643.
Yamada, Y., Ujihara, H., Sada, H., Ban, T., 1995. Pb2+ reduces the current from
NMDA receptors expressed in Xenopus oocytes. FEBS Lett. 377, 390–392.
Yamakura, T., Mori, H., Masaki, H., Shimoji, K., Mishina, M., 1993. Different
sensitivities of NMDA receptor channel subtypes to non-competitive
antagonists. Neuroreport 4, 687–690.
P. Gavazzo et al. / Neurochemistry International 52 (2008) 329–337 337